Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 130

1.

Design, synthesis, and biological evaluation of potent and selective class IIa histone deacetylase (HDAC) inhibitors as a potential therapy for Huntington's disease.

Bürli RW, Luckhurst CA, Aziz O, Matthews KL, Yates D, Lyons KA, Beconi M, McAllister G, Breccia P, Stott AJ, Penrose SD, Wall M, Lamers M, Leonard P, Müller I, Richardson CM, Jarvis R, Stones L, Hughes S, Wishart G, Haughan AF, O'Connell C, Mead T, McNeil H, Vann J, Mangette J, Maillard M, Beaumont V, Munoz-Sanjuan I, Dominguez C.

J Med Chem. 2013 Dec 27;56(24):9934-54. doi: 10.1021/jm4011884. Epub 2013 Dec 5.

PMID:
24261862
[PubMed - indexed for MEDLINE]
2.

Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group.

Lobera M, Madauss KP, Pohlhaus DT, Wright QG, Trocha M, Schmidt DR, Baloglu E, Trump RP, Head MS, Hofmann GA, Murray-Thompson M, Schwartz B, Chakravorty S, Wu Z, Mander PK, Kruidenier L, Reid RA, Burkhart W, Turunen BJ, Rong JX, Wagner C, Moyer MB, Wells C, Hong X, Moore JT, Williams JD, Soler D, Ghosh S, Nolan MA.

Nat Chem Biol. 2013 May;9(5):319-25. doi: 10.1038/nchembio.1223. Epub 2013 Mar 24.

PMID:
23524983
[PubMed - indexed for MEDLINE]
3.

Oral administration of the pimelic diphenylamide HDAC inhibitor HDACi 4b is unsuitable for chronic inhibition of HDAC activity in the CNS in vivo.

Beconi M, Aziz O, Matthews K, Moumné L, O'Connell C, Yates D, Clifton S, Pett H, Vann J, Crowley L, Haughan AF, Smith DL, Woodman B, Bates GP, Brookfield F, Bürli RW, McAllister G, Dominguez C, Munoz-Sanjuan I, Beaumont V.

PLoS One. 2012;7(9):e44498. doi: 10.1371/journal.pone.0044498. Epub 2012 Sep 4.

PMID:
22973455
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington's disease.

Jia H, Pallos J, Jacques V, Lau A, Tang B, Cooper A, Syed A, Purcell J, Chen Y, Sharma S, Sangrey GR, Darnell SB, Plasterer H, Sadri-Vakili G, Gottesfeld JM, Thompson LM, Rusche JR, Marsh JL, Thomas EA.

Neurobiol Dis. 2012 May;46(2):351-61.

PMID:
22590724
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Design, synthesis, biological evaluation, and structural characterization of potent histone deacetylase inhibitors based on cyclic alpha/beta-tetrapeptide architectures.

Montero A, Beierle JM, Olsen CA, Ghadiri MR.

J Am Chem Soc. 2009 Mar 4;131(8):3033-41. doi: 10.1021/ja809508f.

PMID:
19239270
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Towards isozyme-selective HDAC inhibitors for interrogating disease.

Gupta P, Reid RC, Iyer A, Sweet MJ, Fairlie DP.

Curr Top Med Chem. 2012;12(14):1479-99. Review.

PMID:
22827519
[PubMed - indexed for MEDLINE]
7.

Crebinostat: a novel cognitive enhancer that inhibits histone deacetylase activity and modulates chromatin-mediated neuroplasticity.

Fass DM, Reis SA, Ghosh B, Hennig KM, Joseph NF, Zhao WN, Nieland TJ, Guan JS, Kuhnle CE, Tang W, Barker DD, Mazitschek R, Schreiber SL, Tsai LH, Haggarty SJ.

Neuropharmacology. 2013 Jan;64:81-96. doi: 10.1016/j.neuropharm.2012.06.043. Epub 2012 Jul 4.

PMID:
22771460
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Inhibition of class II histone deacetylases in the spinal cord attenuates inflammatory hyperalgesia.

Bai G, Wei D, Zou S, Ren K, Dubner R.

Mol Pain. 2010 Sep 7;6:51. doi: 10.1186/1744-8069-6-51.

PMID:
20822541
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases.

Lahm A, Paolini C, Pallaoro M, Nardi MC, Jones P, Neddermann P, Sambucini S, Bottomley MJ, Lo Surdo P, Carfí A, Koch U, De Francesco R, Steinkühler C, Gallinari P.

Proc Natl Acad Sci U S A. 2007 Oct 30;104(44):17335-40. Epub 2007 Oct 23.

PMID:
17956988
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Design, synthesis and preliminary bioactivity studies of 1,3,4-thiadiazole hydroxamic acid derivatives as novel histone deacetylase inhibitors.

Guan P, Sun F, Hou X, Wang F, Yi F, Xu W, Fang H.

Bioorg Med Chem. 2012 Jun 15;20(12):3865-72. doi: 10.1016/j.bmc.2012.04.032. Epub 2012 Apr 21.

PMID:
22579621
[PubMed - indexed for MEDLINE]
11.

Towards selective inhibition of histone deacetylase isoforms: what has been achieved, where we are and what will be next.

Thaler F, Mercurio C.

ChemMedChem. 2014 Mar;9(3):523-6. doi: 10.1002/cmdc.201300413. Review.

PMID:
24730063
[PubMed - indexed for MEDLINE]
12.

Protein kinase D1 mediates class IIa histone deacetylase phosphorylation and nuclear extrusion in intestinal epithelial cells: role in mitogenic signaling.

Sinnett-Smith J, Ni Y, Wang J, Ming M, Young SH, Rozengurt E.

Am J Physiol Cell Physiol. 2014 May 15;306(10):C961-71. doi: 10.1152/ajpcell.00048.2014. Epub 2014 Mar 19.

PMID:
24647541
[PubMed - indexed for MEDLINE]
13.

[Synthesis and activity of some new histone deacetylases inhibitors].

Cheng YH, Guo YS, Han HZ, Wang N, Zhang GH, Guo ZR, Wu S.

Yao Xue Xue Bao. 2010 Jun;45(6):735-41. Chinese.

PMID:
20939182
[PubMed - indexed for MEDLINE]
14.

Design and synthesis of novel histone deacetylase inhibitor derived from nuclear localization signal peptide.

Canzoneri JC, Chen PC, Oyelere AK.

Bioorg Med Chem Lett. 2009 Dec 1;19(23):6588-90. doi: 10.1016/j.bmcl.2009.10.028. Epub 2009 Oct 13.

PMID:
19854643
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Synthesis and biological characterization of amidopropenyl hydroxamates as HDAC inhibitors.

Thaler F, Varasi M, Colombo A, Boggio R, Munari D, Regalia N, Rozio MG, Reali V, Resconi AE, Mai A, Gagliardi S, Dondio G, Minucci S, Mercurio C.

ChemMedChem. 2010 Aug 2;5(8):1359-72. doi: 10.1002/cmdc.201000166.

PMID:
20572281
[PubMed - indexed for MEDLINE]
16.

2-Trifluoroacetylthiophenes, a novel series of potent and selective class II histone deacetylase inhibitors.

Jones P, Bottomley MJ, Carfí A, Cecchetti O, Ferrigno F, Lo Surdo P, Ontoria JM, Rowley M, Scarpelli R, Schultz-Fademrecht C, Steinkühler C.

Bioorg Med Chem Lett. 2008 Jun 1;18(11):3456-61. doi: 10.1016/j.bmcl.2008.02.026. Epub 2008 Feb 14.

PMID:
18440229
[PubMed - indexed for MEDLINE]
17.

Design, synthesis, and biological evaluation of 2-aminobenzanilide derivatives as potent and selective HDAC inhibitors.

Stolfa DA, Stefanachi A, Gajer JM, Nebbioso A, Altucci L, Cellamare S, Jung M, Carotti A.

ChemMedChem. 2012 Jul;7(7):1256-66. doi: 10.1002/cmdc.201200193. Epub 2012 May 24.

PMID:
22628266
[PubMed - indexed for MEDLINE]
18.

Design, synthesis, and biological activity of hydroxamic tertiary amines as histone deacetylase inhibitors.

Terracciano S, Chini MG, Riccio R, Bruno I, Bifulco G.

ChemMedChem. 2012 Apr;7(4):694-702. doi: 10.1002/cmdc.201100531. Epub 2012 Jan 25.

PMID:
22278987
[PubMed - indexed for MEDLINE]
19.

Design and synthesis of aryl ether and sulfone hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.

Pabba C, Gregg BT, Kitchen DB, Chen ZJ, Judkins A.

Bioorg Med Chem Lett. 2011 Jan 1;21(1):324-8. doi: 10.1016/j.bmcl.2010.11.006. Epub 2010 Nov 5.

PMID:
21109435
[PubMed - indexed for MEDLINE]
20.

Synthesis and biological characterization of spiro[2H-(1,3)-benzoxazine-2,4'-piperidine] based histone deacetylase inhibitors.

Thaler F, Varasi M, Abate A, Carenzi G, Colombo A, Bigogno C, Boggio R, Zuffo RD, Rapetti D, Resconi A, Regalia N, Vultaggio S, Dondio G, Gagliardi S, Minucci S, Mercurio C.

Eur J Med Chem. 2013 Jun;64:273-84. doi: 10.1016/j.ejmech.2013.03.061. Epub 2013 Apr 10.

PMID:
23644210
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk